Complete financial analysis of Lupin Limited (LUPIN.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lupin Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Hugel, Inc. (145020.KQ) Income Statement Analysis – Financial Results
- Barnes Group Inc. (B) Income Statement Analysis – Financial Results
- Basetrophy Group Holdings Limited (8460.HK) Income Statement Analysis – Financial Results
- AstraZeneca PLC (AZNCF) Income Statement Analysis – Financial Results
- TC ENERGY CORP PREF SERIES 7 (TRP-PD.TO) Income Statement Analysis – Financial Results
Lupin Limited (LUPIN.NS)
About Lupin Limited
Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infective, nonsteroidal anti-inflammatory drug therapy, respiratory, women's health, and anti-tuberculosis. The company is also involved in the provision of biosimilar and over-the-counter products; specialty products; and drug discovery and development programs in the therapeutic areas of oncology, immunology, and metabolic disorders, as well as bio clinical research activities. Lupin Limited network consists of 18 labs, 280 LupiMitra collection centers, and 450 pick-up points. It operates in India, the United States, the United Kingdom, South Africa, Australia, the Philippines, Germany, the Netherlands, Mexico, and Brazil. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 196.56B | 162.70B | 161.93B | 149.27B | 151.43B | 163.69B | 155.52B | 169.93B | 136.82B | 125.86B | 110.89B | 94.50B | 70.83B | 57.07B | 47.41B | 37.76B | 27.06B | 20.14B | 16.95B | 12.61B | 12.15B |
| Cost of Revenue | 95.00B | 67.80B | 70.88B | 59.17B | 59.72B | 63.11B | 57.48B | 56.03B | 48.01B | 45.22B | 40.96B | 37.86B | 26.04B | 22.38B | 19.69B | 16.04B | 11.64B | 9.32B | 8.26B | 6.44B | 6.22B |
| Gross Profit | 101.57B | 94.90B | 91.05B | 90.10B | 91.71B | 100.59B | 98.04B | 113.90B | 88.81B | 80.64B | 69.93B | 56.64B | 44.79B | 34.69B | 27.71B | 21.72B | 15.43B | 10.82B | 8.69B | 6.17B | 5.93B |
| Gross Profit Ratio | 51.67% | 58.33% | 56.23% | 60.36% | 60.56% | 61.45% | 63.04% | 67.03% | 64.91% | 64.07% | 63.06% | 59.93% | 63.24% | 60.78% | 58.46% | 57.51% | 57.00% | 53.71% | 51.28% | 48.93% | 48.78% |
| Research & Development | 15.27B | 12.80B | 14.02B | 14.32B | 15.54B | 15.01B | 17.08B | 23.10B | 16.04B | 10.99B | 9.29B | 7.10B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 13.87B | 10.49B | 9.15B | 8.63B | 9.38B | 6.93B | 6.01B | 6.63B | 6.23B | 3.87B | 4.57B | 3.67B | 11.36B | 16.35B | 13.30B | 10.36B | 7.99B | 5.69B | 4.77B | 3.51B | 2.61B |
| Selling & Marketing | 12.16B | 10.75B | 9.81B | 9.09B | 9.64B | 11.64B | 10.28B | 9.32B | 7.91B | 7.12B | 6.52B | 6.05B | 6.44B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 59.73B | 21.24B | 18.97B | 17.73B | 19.02B | 18.57B | 16.29B | 15.95B | 14.14B | 10.99B | 11.09B | 9.72B | 17.80B | 16.35B | 13.30B | 10.36B | 7.99B | 5.69B | 4.77B | 3.51B | 2.61B |
| Other Expenses | 0.00 | 733.60M | 98.50M | 417.30M | 410.40M | 476.60M | 286.70M | 219.40M | 53.40M | 24.30M | 27.30M | 20.10M | -115.00M | 8.05B | 5.67B | 4.80B | 1.66B | 675.50M | 1.36B | 1.43B | 882.30M |
| Operating Expenses | 102.73B | 86.50B | 85.54B | 72.71B | 77.82B | 83.15B | 77.34B | 75.08B | 56.61B | 47.35B | 41.66B | 37.16B | 32.06B | 24.40B | 18.97B | 15.16B | 9.65B | 6.37B | 6.13B | 4.94B | 3.49B |
| Cost & Expenses | 171.44B | 154.30B | 156.42B | 131.88B | 137.54B | 146.26B | 134.83B | 131.12B | 104.63B | 92.57B | 82.63B | 75.02B | 58.10B | 46.78B | 38.66B | 31.20B | 21.29B | 15.69B | 14.39B | 11.38B | 9.72B |
| Interest Income | 462.30M | 324.30M | 960.00M | 396.90M | 1.29B | 664.60M | 195.60M | 169.00M | 188.00M | 130.60M | 158.60M | 141.50M | 80.40M | 43.90M | 48.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.12B | 2.74B | 1.07B | 1.17B | 3.40B | 2.68B | 1.59B | 1.25B | 305.30M | 55.90M | 99.00M | 240.30M | 354.70M | 324.60M | -336.40M | 498.60M | 373.50M | 372.20M | 312.80M | 282.50M | 0.00 |
| Depreciation & Amortization | 9.96B | 8.41B | 8.19B | 8.53B | 9.70B | 8.46B | 10.86B | 9.12B | 4.64B | 4.35B | 2.61B | 3.32B | 2.28B | 1.71B | 1.24B | 879.90M | 647.40M | 466.10M | 408.80M | 336.20M | 295.30M |
| EBITDA | 36.97B | 18.05B | -4.39B | 26.48B | 20.32B | 25.34B | 18.17B | 45.87B | 38.53B | 38.59B | 31.18B | 22.98B | 14.55B | 12.00B | 9.98B | 7.44B | 6.42B | 4.91B | 2.98B | 1.57B | 2.73B |
| EBITDA Ratio | 18.81% | 11.50% | 14.50% | 17.39% | 19.16% | 19.03% | 20.57% | 28.18% | 27.73% | 30.68% | 28.25% | 23.98% | 21.15% | 21.03% | 21.05% | 19.70% | 23.73% | 24.40% | 17.56% | 12.44% | 22.48% |
| Operating Income | 27.76B | 8.52B | 12.58B | 17.54B | 13.71B | 17.15B | 20.70B | 38.81B | 32.19B | 33.29B | 28.26B | 19.48B | 12.73B | 10.29B | 8.74B | 6.56B | 5.78B | 4.45B | 2.57B | 1.23B | 2.44B |
| Operating Income Ratio | 14.12% | 5.24% | 7.77% | 11.75% | 9.05% | 10.48% | 13.31% | 22.84% | 23.53% | 26.45% | 25.49% | 20.61% | 17.97% | 18.03% | 18.44% | 17.37% | 21.34% | 22.08% | 15.15% | 9.77% | 20.05% |
| Total Other Income/Expenses | -3.54B | -1.73B | -26.30B | -776.00M | -6.13B | -3.06B | -15.23B | -1.36B | 1.05B | 853.60M | -413.70M | -945.60M | -469.30M | -344.10M | -384.90M | -498.60M | -373.50M | -372.20M | -312.80M | -282.50M | -525.90M |
| Income Before Tax | 24.22B | 7.16B | -13.72B | 16.76B | 7.57B | 15.17B | 5.47B | 35.43B | 34.33B | 34.15B | 28.32B | 19.25B | 11.96B | 9.96B | 8.36B | 6.06B | 5.40B | 4.07B | 2.26B | 949.60M | 1.91B |
| Income Before Tax Ratio | 12.32% | 4.40% | -8.47% | 11.23% | 5.00% | 9.27% | 3.52% | 20.85% | 25.09% | 27.13% | 25.54% | 20.37% | 16.89% | 17.46% | 17.63% | 16.05% | 19.96% | 20.23% | 13.30% | 7.53% | 15.73% |
| Income Tax Expense | 4.87B | 2.69B | 1.37B | 4.49B | 11.57B | 9.02B | 2.88B | 9.79B | 11.54B | 9.70B | 9.62B | 5.84B | 3.09B | 1.17B | 1.36B | 983.00M | 1.32B | 988.10M | 521.00M | 27.40M | 518.00M |
| Net Income | 19.14B | 4.30B | -15.28B | 12.17B | -2.69B | 6.07B | 2.51B | 25.57B | 22.71B | 24.03B | 18.36B | 13.14B | 8.68B | 8.63B | 6.82B | 5.02B | 4.08B | 3.09B | 1.73B | 922.20M | 1.39B |
| Net Income Ratio | 9.74% | 2.64% | -9.44% | 8.15% | -1.78% | 3.71% | 1.62% | 15.05% | 16.60% | 19.09% | 16.56% | 13.91% | 12.25% | 15.11% | 14.38% | 13.28% | 15.08% | 15.32% | 10.20% | 7.31% | 11.46% |
| EPS | 42.05 | 9.46 | -33.65 | 26.84 | -5.95 | 13.41 | 5.56 | 56.69 | 50.25 | 53.54 | 40.99 | 29.39 | 19.43 | 19.36 | 15.84 | 12.17 | 10.00 | 7.56 | 4.22 | 2.24 | 2.07 |
| EPS Diluted | 41.87 | 9.41 | -33.65 | 26.72 | -5.95 | 13.36 | 5.54 | 56.46 | 49.96 | 53.20 | 40.79 | 29.26 | 19.36 | 19.25 | 15.56 | 12.04 | 9.96 | 7.52 | 4.21 | 2.23 | 2.07 |
| Weighted Avg Shares Out | 455.29M | 454.69M | 454.04M | 453.28M | 452.71M | 452.24M | 451.85M | 451.12M | 450.11M | 448.87M | 447.98M | 447.83M | 447.83M | 447.83M | 447.83M | 447.83M | 447.83M | 447.83M | 447.83M | 447.83M | 447.83M |
| Weighted Avg Shares Out (Dil) | 457.23M | 456.95M | 454.04M | 455.24M | 452.71M | 454.12M | 453.33M | 452.97M | 452.78M | 451.71M | 450.24M | 447.83M | 447.83M | 447.83M | 447.83M | 447.83M | 447.83M | 447.83M | 447.83M | 447.83M | 447.83M |
Source: https://incomestatements.info
Category: Stock Reports